The pooled ORR from RCTs (26%, 95%CIs: 20%-33%) and single-arm trials (34%, 95%CIs: 27%-43%) consolidates the view that SG delivers clinically meaningful tumor shrinkage in both TNBC and HR+/HER2- mBC. This evidence concerns the gene ERBB2 and neoplasm.